The Targeted Drug Delivery Lab is primarily dedicated to using nano and polymer-technology to improve the delivery of chemotherapeutic drugs towards sites of tumour growth and metastasis, while limiting drug exposure throughout the rest of the body. In particular, our focus is on eliminating cancers that have spread to regional (sentinel) lymph nodes and the lungs with the view to maximise the successful treatment of metastatic cancers and improve survival rates for cancer patients.

The group also have an interest in evaluating how nanoparticles and nanomedicines are cleared from healthy and diseased lungs after inhaled delivery and in understanding the fundamental basis for high inter-individual variability in the pharmacokinetics of macromolecular drugs and nanomedicines.

Group Head

Research staff

PhD students

  • Chris Subasic
  • Ashok Kothapalli

View publications on Google Scholar.

  1. Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: a Viable Approach to Treating Idiopathic Pulmonary Fibrosis. Kaminskas LM, Landersdorfer CB, Bischof RJ, Leong N, Ibrahim J, Davies AN, Pham S, Beck S, Montgomery AB, Surber MW. Pharm Res. 2019 Dec 10;37(1):3.
  2. dendPoint: a web resource for dendrimer pharmacokinetics investigation and prediction. Kaminskas LM, Pires DEV, Ascher DB. Sci Rep. 2019 Oct 29;9(1):15465.
  3. Local inflammation alters the lung disposition of a drug loaded pegylated liposome after pulmonary dosing to rats. Haque S, Feeney O, Meeusen E, Boyd BJ, McIntosh MP, Pouton CW, Whittaker M, Kaminskas LM. J Control Release. 2019 May 29;307:32-43.
  4. *A 30 kDa polyethylene glycol-enfuvirtide complex enhances the exposure of enfuvirtide in lymphatic viral reservoirs in rats. Kaminskas LM, Williams CC, Leong NJ, Chan LJ, Butcher NJ, Feeney OM, Porter CJH, Tyssen D, Tachedjian G, Ascher DB. Eur J Pharm Biopharm. 2019 Apr;137:218-226.
  5. Reducing Dendrimer Generation and PEG Chain Length Increases Drug Release and Promotes Anticancer Activity of PEGylated Polylysine Dendrimers Conjugated with Doxorubicin via a Cathepsin-Cleavable Peptide Linker. Mehta D, Leong N, McLeod VM, Kelly BD, Pathak R, Owen DJ, Porter CJH, Kaminskas LM. Mol Pharm. 2018 Oct 1;15(10):4568-4576.
  6. Doxorubicin Conjugation and Drug Linker Chemistry Alter the Intravenous and Pulmonary Pharmacokinetics of a PEGylated Generation 4 Polylysine Dendrimer in Rats. Leong NJ, Mehta D, McLeod VM, Kelly BD, Pathak R, Owen DJ, Porter CJH, Kaminskas LM. J Pharm Sci. 2018 Sep;107(9):2509-2513.
  7. A comparison of the lung clearance kinetics of solid lipid nanoparticles and liposomes by following the 3H-labelled structural lipids after pulmonary delivery in rats. Haque S, Whittaker M, McIntosh MP, Pouton CW, Phipps S, Kaminskas LM. Eur J Pharm Biopharm. 2018 Apr;125:1-12
  8. Microfluidic preparation of drug-loaded PEGylated liposomes, and the impact of liposome size on tumour retention and penetration. Dong YD, Tchung E, Nowell C, Kaga S, Leong N, Mehta D, Kaminskas LM, Boyd BJ. J Liposome Res. 2019 Mar;29(1):1-9.
  9. Influence of Size and Shape on the Biodistribution of Nanoparticles Prepared by Polymerization-Induced Self-Assembly. Kaga S, Truong NP, Esser L, Senyschyn D, Sanyal A, Sanyal R, Quinn JF, Davis TP, Kaminskas LM, Whittaker MR. Biomacromolecules. 2017 Dec 11;18(12):3963-3970
  10. An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration. Chan LJ, Feeney OM, Leong NJ, McLeod VM, Porter CJH, Williams CC, Kaminskas LM. Biomacromolecules. 2017 Sep 11;18(9):2866-2875.
  11. Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers. Haque S, McLeod VM, Jones S, Fung S, Whittaker M, McIntosh M, Pouton C, Owen DJ, Porter CJH, Kaminskas LM. Eur J Pharm Biopharm. 2017 Oct;119:408-418
  12. *Disposition and Safety of Inhaled Biodegradable Nanomedicines: Opportunities and Challenges. Haque S, Whittaker MR, McIntosh MP, Pouton CW, Kaminskas LM. Nanomedicine. 2016; 12(6): 1703-24
  13. Conjugation of 10 kDa Linear PEG onto Trastuzumab Fab' Is Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological Activity. Chan LJ, Ascher DB, Yadav R, Bulitta JB, Williams CC, Porter CJ, Landersdorfer CB, Kaminskas LM. Mol Pharm. 2016; 13(4): 1229-41
  14. A Comparison of the Pharmacokinetics and Pulmonary Lymphatic Exposure of a Generation 4 PEGylated Dendrimer Following Intravenous and Aerosol Administration to Rats and Sheep. Ryan GM, Bischof RJ, Enkhbaatar P, McLeod VM, Chan LJ, Jones SA, Owen DJ, Porter CJ, Kaminskas LM. Pharm Res. 2016;33(2): 510-25
  15. From sewer to saviour – targeting the lymphatic system to promote drug disposition and activity. Trevaskis NT, Kaminskas LM, Porter CJH. Nature Reviews Drug Discovery. 2015; 14(11); 781-803.
  16. PEGylated interferon displays differences in plasma clearance and bioavailability between male and female mice and between female immunocompetent C57Bl/6J and athymic nude mice. Landersdorfer CB, Caliph SM, Shackleford DM, Ascher DB, Kaminskas LM. J Pharm Sci. 2015 May;104(5):1848-55.
  17. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. Kaminskas LM, McLeod VM, Ryan GM, Kelly BD, Haynes JM, Williamson M, Thienthong N, Owen DJ, Porter CJ. J Control Release. 2014;183:18-26

Find out more about our research environment and how to apply to do a short or long-term research project with us.